@misc{oai:repo.qst.go.jp:00061940,
 author = {Yamada, Shigeru and Katou, Hirotoshi and Hara, Ryusuke and Yasuda, Shigeo and Kamada, Tadashi and Tsujii, Hirohiko and Tsuji, Hiroshi and Yanagi, Takeshi and Mizoe, Junetsu and Miyamoto, Tadaaki and Yoshikawa, Kyosan and Kishimoto, Riwa and Kandatsu, Susumu and Saisho, Hiromitsu and 山田 滋 and 加藤 博敏 and 原 竜介 and 安田 茂雄 and 鎌田 正 and 辻井 博彦 and 辻 比呂志 and 柳 剛 and 溝江 純悦 and 宮本 忠昭 and 吉川 京燦 and 岸本 理和 and 神立 進 and 税所 宏光},
 month = {Nov},
 note = {Adenocarcinoma of the pancreas continues to be a significant source of cancer mortality in Japan, resulting in approximately 19,000 deaths a year. It is the fifth leading cause of cancer-related deaths in Japan, with a less than 5% 5-year expected survival rate [1]. About 70-75% of patients with pancreas cancer present with locally advanced disease or distant metastases and have a median survival time of only 6 months. For unresectable pancreas cancer, the median survival time with extermal beam radiation (EBRT) was better than with surgical bypass [2] or stents alone [3]. The median survival OF EBRT alone was 4 to 7 months [4]. The median survival with combined EBRT and chemotherapy for locally unresectable tumor are 8 to 10 months [5] and better than with the EBRT alone. Local failure of these combined therapies was still 26 to 48 %. On the other hand, surgery with curative intent is undertaken in 15-20% of patients. Even after resection, the predicted 5-year survival rates are still less than 20% [1]. Local recurrences in the pancreatic bed are seen in 50% of the patients undergoing presumed curative resection [6]. We examined the effect of carbon ion therapy in terms of reducing the rate of local recurrence in patients with locally advanced adenocarcinoma of the pancreas or undergoing resection for adenocarcinoma of the pancreas., NIRS-CNAO Joint Symposium on Carbon Ion Radiotherapy},
 title = {Pancreas Cancer},
 year = {2006}
}